Co-Diagnostics Inc (CODX) 2026 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Thank you for standing by. At this time, I would like to welcome everyone to the Co-Diagnostics, Inc. first quarter 2026 earnings webcast. (Operator Instructions)

    感謝您耐心等候。此刻,我謹代表主辦方歡迎各位參加 Co-Diagnostics, Inc. 2026 年第一季財報網路直播。(接線員指示)

  • I would now like to turn the conference over to Andrew Benson, Head of Investor Relations. The floor is yours.

    現在我想將會議交給投資人關係主管 Andrew Benson。請開始。

  • Andrew Benson - Head - Investor Relations

    Andrew Benson - Head - Investor Relations

  • Good afternoon, everyone. Thank you all for participating in today's conference call. On the line today from Co-Diagnostics, we have Dwight Egan, Chief Executive Officer; and Brian Brown, Chief Financial Officer. Earlier today, Co-Diagnostics released financial results from the first quarter ended March 31, 2026.

    各位下午好。感謝各位參與今天的電話會議。今天在線上代表 Co-Diagnostics 的有執行長 Dwight Egan,以及財務長 Brian Brown。稍早 Co-Diagnostics 已公布截至 2026 年 3 月 31 日止第一季的財務結果。

  • A copy of the press release is available on the company's website. We will begin with management's prepared remarks and then open up the call to analysts for Q&A. Before we begin, we would like to inform listeners that certain statements made by Co-Diagnostics during this call, which are not historical facts, are forward-looking statements.

    新聞稿副本可於公司網站取得。我們將先由管理層發表準備好的談話,之後開放分析師進行問答。在開始之前,我們提醒聽眾,Co-Diagnostics 在本次電話會議中所作的某些非歷史事實之陳述,屬於前瞻性陳述。

  • In addition to diagnostic test developments and timing for commencement of clinical evaluations, this includes statements concerning the company's Co-Dx PCR testing platform, which requires regulatory approval and marketing authorization for diagnostic use and is not currently for sale. Actual outcomes and results may differ materially from what is expressed or implied in any statement.

    除診斷檢測的開發進展與臨床評估啟動時程外,亦包括關於公司 Co-Dx PCR 檢測平台的陳述;該平台用於診斷用途需取得監管核准與上市許可,且目前尚未對外銷售。實際結果與表現可能與任何陳述中明示或暗示者存在重大差異。

  • Important factors which could cause actual results to differ materially from those in these forward-looking statements are detailed in Co-Diagnostics' filings with the SEC. Co-Diagnostics assumes no obligation and expressly disclaims any duty to update any forward-looking statements to reflect events or circumstances occurring after this call or to reflect the occurrence of unanticipated events.

    可能導致實際結果與這些前瞻性陳述所述存在重大差異的重要因素,已詳載於 Co-Diagnostics 向美國證券交易委員會(SEC)提交的文件中。Co-Diagnostics 不承擔任何義務,並明確否認任何更新前瞻性陳述之責任,以反映本次電話會議後發生的事件或情況,或反映未預期事件的發生。

  • In addition, the company may discuss certain non-GAAP financial measures during today's call. These non-GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. We refer you to the company's earnings release issued shortly before this call, which contains reconciliations to the non-GAAP financial measures presented to their most comparable GAAP results.

    此外,公司可能在今天的電話會議中討論某些非 GAAP 財務衡量指標。這些非 GAAP 財務衡量指標不應被視為 GAAP 結果的替代,並應與 GAAP 結果一併閱讀。請參閱本次電話會議前不久發布的公司財報新聞稿,其中包含所呈列非 GAAP 財務衡量指標與其最可比 GAAP 結果之調節表。

  • At this time, I would like to turn the call over to Co-Diagnostics' Chief Executive Officer, Dwight Egan. Dwight?

    此刻,我想將電話會議交給 Co-Diagnostics 執行長 Dwight Egan。Dwight?

  • Dwight Egan - Chairman of the Board, Chief Executive Officer

    Dwight Egan - Chairman of the Board, Chief Executive Officer

  • Thank you, everyone, for joining us today and for your continued support of Co-Diagnostics. This continues to be an active and important period for our business as we execute on the opportunities ahead and remain focused on positioning the company for its next phase of growth. The work we are doing across the organization is connected. And together, it reflects the progress we are making towards commercialization as well as the broader strategy we have put in place to create long-term value.

    感謝各位今天加入我們,並持續支持 Co-Diagnostics。在我們把握前方機會、並專注於為公司下一階段成長做好定位之際,這段期間對我們的業務而言仍然活躍且重要。我們在整個組織所做的工作彼此相互連結。整體而言,這反映了我們在邁向商業化方面所取得的進展,以及我們為創造長期價值所制定的更廣泛策略。

  • As we look ahead, our efforts remain centered on a few key areas: advancing our clinical and commercialization pipeline, continuing to build out our strategy in India through CoSara, progressing our CoMira joint venture in Saudi Arabia and the broader MENA region, and further enhancing our platform through connectivity, automation and AI-driven capabilities.

    展望未來,我們的努力仍聚焦於幾個關鍵領域:推進臨床與商業化產品線、透過 CoSara 持續在印度建立策略、推動我們在沙烏地阿拉伯及更廣泛中東與北非(MENA)地區的 CoMira 合資事業,以及透過連線性、自動化與 AI 驅動能力進一步強化我們的平台。

  • Taken together, these priorities reflect a business that is increasingly focused on execution, scalability and market readiness. Let me start with our clinical and commercialization pipeline. Our upper respiratory multiplex test remains a key step toward market readiness. As a reminder, this test was originally designed to detect Flu A, Flu B, COVID-19 and RSV on a single platform.

    綜合而言,這些優先事項反映出我們的業務正日益聚焦於執行力、可擴展性與市場就緒度。我先從臨床與商業化產品線談起。我們的上呼吸道多重檢測仍是邁向市場就緒的重要一步。提醒各位,該檢測最初設計為可在單一平台上偵測 A 型流感、B 型流感、COVID-19 與 RSV。

  • We have now completed enrollment in the clinical study, with more than 1,400 patients enrolled. Based on current epidemiological conditions, COVID prevalence was lower than expected. And as we have shared previously, we are planning an initial submission focused on Flu A, Flu B and RSV. This approach allows us to advance timelines while maintaining the ability to incorporate COVID at a later stage, if appropriate.

    我們現已完成臨床研究的受試者招募,納入超過 1,400 名患者。基於目前的流行病學狀況,COVID 的盛行率低於預期。如同我們先前分享的,我們規劃先以 A 型流感、B 型流感與 RSV 為重點進行初次送件。此作法讓我們得以在保留日後(如適當)納入 COVID 的能力之同時,加速時程推進。

  • And it reflects market dynamics rather than any limitation of the platform itself. Based on the company's assessment, management believes the study has generated the data intended to support a 510(k) submission with the FDA. At the same time, we have maintained the clinical study infrastructure in a paused state to preserve flexibility in the event additional data is requested.

    這反映的是市場動態,而非平台本身的任何限制。根據公司評估,管理層認為該研究已產生預期用以支持向 FDA 提交 510(k) 申請的數據。同時,我們已將臨床研究基礎設施維持在暫停狀態,以便在需要補充資料時保留彈性。

  • Our immediate focus is now on finalizing the analytical studies and documentation for submission to the FDA. We are preparing the submission to obtain clearance for CLIA-waived point-of-care use. And based on our current progress, we anticipate filing in the third quarter of this year, subject to completion of internal validation, submission preparation activities and ongoing regulatory assessment.

    我們目前的當務之急是完成分析性研究與送件所需文件,以提交 FDA。我們正準備送件以取得 CLIA 豁免之定點照護(point-of-care)用途許可。依據目前進度,我們預期將於今年第三季提出申請,但仍取決於內部驗證完成、送件準備作業以及持續的法規評估。

  • Turning to India. This has been a core part of our strategy for nearly nine years. And over that time, we have built a meaningful foundation through our CoSara joint venture in one of the largest health care markets in the world. Today, CoSara has a nationwide commercial presence, has served hundreds of laboratory customers and has 15 clinical laboratory PCR tests cleared by the CDSCO, India's regulatory body.

    接著談印度。這一直是我們近九年來策略的核心部分。在此期間,我們透過 CoSara 合資企業,在全球最大的醫療保健市場之一建立了具意義的基礎。目前,CoSara 已具備全國性的商業布局,服務過數百家實驗室客戶,並有 15 項臨床實驗室 PCR 檢測獲得印度監管機構 CDSCO 核准。

  • We are now preparing to manufacture the PCR Pro instrument and associated consumables locally in India, which represents an important step towards commercialization. CoSara has also now received a CDSCO license to manufacture the PCR Pro instrument, an important regulatory milestone that supports this transition. In addition, we have expanded CoSara's commercial and distribution territory across South Asia, increasing our total addressable market to approximately $13 billion.

    我們目前正準備在印度本地製造 PCR Pro 儀器及其相關耗材,這代表邁向商業化的重要一步。CoSara 也已取得 CDSCO 核發的 PCR Pro 儀器製造許可,這是一項重要的法規里程碑,支持此一轉型。此外,我們已將 CoSara 的商業與經銷版圖擴展至南亞各地,使我們的總可服務市場(TAM)提升至約 130 億美元。

  • As CoSara continues to mature, we believe it has reached a stage where it can stand on its own as a public entity, which could provide an alternative path to access capital and support future growth while also creating additional value for Co-Dx shareholders. We continue to evaluate the strategic alternatives, including a potential SPAC transaction, to support the capital needs required to fully execute on this opportunity.

    隨著 CoSara 持續成熟,我們認為其已達到可作為獨立公開實體運作的階段,這可能提供另一條取得資本的途徑並支持未來成長,同時也為 Co-Dx 股東創造額外價值。我們持續評估各項策略替代方案,包括潛在的 SPAC 交易,以支援充分落實此一機會所需的資本需求。

  • This process remains active with ongoing engagement from advisers and potential counterparties, including parties now under NDA with access to the data room. While discussions remain ongoing, no transaction has been agreed to, and there can be no assurance that any transaction will result from these discussions.

    此流程在顧問與潛在交易對手的持續參與下仍在進行中,其中包括目前已簽署保密協議(NDA)並可存取資料室的各方。儘管討論仍在持續,尚未達成任何交易,且無法保證這些討論將促成任何交易。

  • Beyond any potential transaction, CoSara is also central to the advancement of our TB program. Clinical performance studies for TB are scheduled to begin before the end of the month, and we are continuing to make operational progress toward that start. The time and place of this program is particularly compelling as India has the highest global burden of tuberculosis and represents the single largest country market for TB testing in the world by testing volume.

    除任何潛在交易之外,CoSara 亦是推進我們 TB 計畫的核心。TB 的臨床效能研究預計在本月底前啟動,我們也持續在營運面推進,以確保如期開始。此計畫的時機與地點尤具吸引力,因為印度為全球結核病負擔最高的國家,且以檢測量計算,亦是全球 TB 檢測的單一最大國家市場。

  • Recent WHO guidance recommending near point-of-care molecular testing for TB diagnosis, along with the use of tongue swab samples, aligns well with the design of our platform and MTB test. We specifically designed our test to accommodate these types of sample approaches, and we believe this reflects a convergence between our development strategy, supported in part by the Gates Foundation, and the evolving standards now being adopted by major global health organizations.

    近期 WHO 指引建議採用近端照護(near point-of-care)的分子檢測進行 TB 診斷,並搭配使用舌拭子樣本,這與我們平台與 MTB 檢測的設計高度契合。我們在設計檢測時即特別納入可支援此類取樣方式的需求,並相信這反映出我們的開發策略(部分由蓋茲基金會支持)與主要全球衛生組織目前採納之演進標準之間的趨同。

  • As clinical studies begin in support of a submission to the CDSCO, we expect them to represent an important validation point for the program and a meaningful step toward commercialization in India, which we believe we will be positioned to commence as early as the end of the third quarter.

    隨著為支持向 CDSCO 提交申請而展開的臨床研究啟動,我們預期這將成為該計畫的重要驗證節點,並是在印度邁向商業化的重要一步;我們相信最早可於第三季末開始商業化。

  • Turning to the Kingdom of Saudi Arabia. Our CoMira joint venture continues to progress and remains an important part of our international expansion strategy. Saudi Arabia has historically been our largest international market, and this initiative is designed to build on that position by localizing our platform within the Kingdom and across the broader MENA region.

    接著談沙烏地阿拉伯王國。我們的 CoMira 合資企業持續推進,並仍是我們國際擴張策略的重要一環。沙烏地阿拉伯歷來一直是我們最大的國際市場,而此項倡議旨在透過在王國境內及更廣泛的 MENA 地區在地化我們的平台,進一步鞏固該地位。

  • The CoMira model builds on the same localization approach we have used in India, with the goal of establishing manufacturing and distribution capabilities closer to end markets. Last month, CoMira secured approval for an industrial land allocation in Sudair Industrial City following approval by MODON, marking an important step forward as Sudair plays a central role in Saudi Arabia's Vision 2030 initiative.

    CoMira 模式延續我們在印度採用的相同在地化方法,目標是在更接近終端市場之處建立製造與配送能力。上月,CoMira 在獲得 MODON 核准後,取得位於 Sudair 工業城的工業用地分配核准,這是重要的進展,因為 Sudair 在沙烏地阿拉伯「願景 2030」倡議中扮演核心角色。

  • We have also progressed to the next phase of execution, including moving forward with the facility lease and development of the site. We have completed our initial required funding contributions under the joint venture agreement, and the broader project continues to advance.

    我們也已推進至下一階段的執行,包括推動廠房租賃及基地開發。我們已完成合資協議下初始所需的出資,整體專案亦持續推進。

  • Once operational, CoMira has the potential to be among the early domestic manufacturers of molecular diagnostics in Saudi Arabia, which could provide a meaningful advantage in a market that prioritizes local production. Domestically, manufactured medical products are typically given preference in government procurement processes, and we expect that to extend to molecular diagnostics.

    一旦投入營運,CoMira 有潛力成為沙烏地阿拉伯較早期的分子診斷本土製造商之一,這可在重視在地生產的市場中帶來顯著優勢。在政府採購流程中,國內製造的醫療產品通常會獲得優先考量,我們預期分子診斷亦將適用此趨勢。

  • While certain operational steps are still in progress, the broader strategic opportunity remains intact. Importantly, as Co-Dx tests received FDA clearance in the US, the path into Saudi Arabia may be more direct than in some other markets, which could allow for commercial activity ahead of full manufacturing build-out.

    儘管部分營運步驟仍在進行中,整體策略機會仍然存在。重要的是,隨著 Co-Dx 檢測在美國取得 FDA 核准,進入沙烏地阿拉伯的路徑可能比其他部分市場更為直接,這可能使我們在完整製造建置完成前即可展開商業活動。

  • Looking more broadly at the pipeline, we continue to make progress across several important programs as we assess the needs of our target markets and plan for upcoming commercialization. This includes seeing increasing overlapping use cases across certain channels, particularly where the need for upper respiratory testing and TB testing coexist within the same settings, such as skilled nursing and assisted living facilities within the US, potentially opening additional domestic commercialization opportunities for the MTB test.

    更廣泛地看產品線,我們在多項重要計畫上持續取得進展,同時評估目標市場需求並規劃即將到來的商業化。其中包括在某些通路看到日益增加的重疊使用情境,特別是在同一場域同時存在上呼吸道檢測與 TB 檢測需求之處,例如美國的專業護理與輔助生活機構,這可能為 MTB 檢測帶來額外的國內商業化機會。

  • In addition to TB, our HPV program continues to advance through preclinical development and qualification work. We are encouraged by the pace of progress and continue to believe it will become an important part of our test menu. Our Vector program also continues to expand with additional system placements and increasing adoption across public health applications.

    除 TB 外,我們的 HPV 計畫亦持續透過臨床前開發與資格認證工作向前推進。我們對進展速度感到鼓舞,並持續相信其將成為我們檢測選單的重要組成。我們的 Vector 計畫也持續擴展,新增更多系統布建,並在公共衛生應用中獲得更高採用率。

  • From a technology perspective, we have been leveraging machine learning and algorithmic analysis within our platform for many years, and we continue to expand those capabilities. A key component of this strategy is our cloud-connected architecture, which allows us to capture and monitor testing activity in real time across deployed systems.

    從技術角度來看,我們多年來一直在平台中運用機器學習與演算法分析,並持續擴充這些能力。此策略的一個關鍵組成是我們的雲端連線架構,使我們能即時擷取並監控已部署系統的檢測活動。

  • These capabilities support improved operational efficiency, remote system management and broader situational awareness. And over time, we believe they may support enhanced analytical capabilities relating to testing trends and operational insights. We are also continuing to make progress in automation within our manufacturing processes, particularly around consumable production, where advances could become increasingly important as we scale.

    這些能力可支援提升營運效率、遠端系統管理與更全面的態勢掌握。隨著時間推進,我們相信它們也可能支援與檢測趨勢及營運洞察相關的更強分析能力。我們亦持續在製造流程自動化方面取得進展,特別是在耗材生產環節;隨著規模擴大,這些進展可能變得愈發重要。

  • Taken together, these efforts demonstrate the versatility of our platform and its ability to address multiple high-need markets. In closing, the initiatives we have discussed today reflect the continued progress Co-Diagnostics has made over the past several months. Each of these areas strengthens a different part of the business, from international expansion and manufacturing readiness to clinical advancement and platform development.

    綜合而言,這些努力展現了我們平台的多樣性,以及其滿足多個高需求市場的能力。最後,今天討論的各項倡議反映出 Co-Diagnostics 在過去數月持續取得的進展。這些領域各自強化了業務的不同面向,從國際擴張與製造就緒度,到臨床推進與平台開發。

  • Overall, they demonstrate that we are continuing to move the business forward and position the platform for commercialization. We believe we are entering the next phase of growth with a stronger foundation, increasing visibility and a clear path toward key milestones.

    整體而言,這些成果顯示我們持續推動業務向前,並使平台就商業化做好定位。我們相信,在更穩固的基礎、更高的能見度以及通往關鍵里程碑的清晰路徑之下,我們正進入下一階段的成長。

  • With that, I'll now turn the call over to Brian Brown, our Chief Financial Officer, to review our financial results and outlook.

    接下來,我將把電話會議交給我們的財務長 Brian Brown,請他回顧我們的財務結果與展望。

  • Brian Brown - Chief Financial Officer, Company Secretary

    Brian Brown - Chief Financial Officer, Company Secretary

  • Thanks, Dwight, and thank you to everyone who joined today's call. For the first quarter of 2026, total revenue was $146,000, compared to $50,000 in the same period last year. Cost of revenue for the quarter was $194,000, resulting in a loss of approximately $48,000, compared to a gross profit of $29,000 in the prior year period. As we have discussed previously, our current revenue levels remain limited, and cost variability can impact gross margin performance at this stage as we continue to scale.

    謝謝你,Dwight,也感謝今天參與電話會議的各位。2026 年第一季總營收為 146,000 美元,較去年同期的 50,000 美元增加。本季營收成本為 194,000 美元,導致約 48,000 美元的毛損,對比去年同期為 29,000 美元的毛利。如我們先前所討論,目前營收水準仍然有限,在我們持續擴大規模的此階段,成本的變動性可能影響毛利率表現。

  • Total operating expenses for the quarter were $9.2 million, compared to $8.6 million in the same period last year. This increase was primarily driven by higher research and development spending. Research and development expenses were $5.9 million, compared to $4.9 million in the prior year period, with the increase largely driven by spending on the upper respiratory test clinical studies.

    本季總營業費用為 920 萬美元,較去年同期的 860 萬美元增加。此增加主要由較高的研發支出所驅動。研發費用為 590 萬美元,較去年同期的 490 萬美元增加,增幅主要來自上呼吸道檢測臨床研究的支出。

  • Sales and marketing expenses were $0.5 million, compared to $0.7 million in the prior year. And general and administrative expenses were $2.5 million, compared to $2.8 million in Q1 2025. These decreases were primarily driven by lower consulting and personnel-related costs. Net loss for the quarter was $9.1 million or $4.06 per fully diluted share, compared to a net loss of $7.5 million or $7.05 per fully diluted share in the same period last year.

    銷售與行銷費用為50萬美元,較前一年度的70萬美元下降。一般及行政費用為250萬美元,較2025年第一季的280萬美元下降。這些下降主要由較低的顧問費用與人員相關成本所致。本季淨損為910萬美元,或每股完全稀釋後虧損4.06美元,較去年同期淨損750萬美元、或每股完全稀釋後虧損7.05美元相比。

  • The increase in net loss was primarily driven by higher operating expenses and lower other income, including the absence of certain onetime remeasurement gains recognized in the prior year period. Adjusted EBITDA for the quarter was a loss of $8.7 million, compared to a loss of $7.4 million in the prior year period.

    淨損增加主要由較高的營運費用與較低的其他收入所致,其中包括前一年度期間所認列之若干一次性重估收益的缺席。本季調整後EBITDA為虧損870萬美元,較前一年度同期虧損740萬美元相比。

  • Turning to the balance sheet. We ended the quarter with $8.2 million in cash and cash equivalents, compared to $11.9 million at the end of 2025. The change reflects continued investment in our clinical programs and platform development. While we expect to continue generating operating losses in the near term, our focus remains on advancing our clinical pipeline, completing regulatory submissions and positioning the business for future revenue growth.

    接著看資產負債表。本季期末現金及約當現金為820萬美元,較2025年年底的1,190萬美元下降。此變動反映我們持續投資於臨床計畫與平台開發。雖然我們預期短期內仍將持續產生營運虧損,但我們的重點仍在推進臨床產品線、完成監管申報,並為未來營收成長做好布局。

  • At the same time, we remain disciplined in managing our cost structure and prioritizing investments to support key clinical and regulatory milestones. We expect that additional capital will likely be required to fully execute our commercialization and development plans.

    同時,我們在管理成本結構方面仍保持紀律,並優先投入以支持關鍵的臨床與監管里程碑。我們預期,為了完整執行商業化與開發計畫,可能需要額外資本。

  • We will also continue to evaluate financing alternatives, including equity, debt and strategic partnerships to support these objectives, while remaining mindful of dilution and overall capital efficiency. In parallel, we remain focused on securing nondilutive funding opportunities, including grants, where appropriate.

    我們也將持續評估融資替代方案,包括股權、債務及策略夥伴關係,以支持這些目標,同時留意稀釋影響與整體資本效率。同時,在適當情況下,我們也將專注於爭取非稀釋性資金機會,包括補助款。

  • Looking ahead, we remain focused on disciplined capital allocation as we move towards several key inflection points, including clinical submissions and the initial stages of commercialization.

    展望未來,隨著我們邁向數個關鍵拐點(包括臨床申報與商業化初期階段),我們仍將專注於有紀律的資本配置。

  • With that, I will now turn the call back over to Dwight.

    接下來,我把電話交回給Dwight。

  • Dwight Egan - Chairman of the Board, Chief Executive Officer

    Dwight Egan - Chairman of the Board, Chief Executive Officer

  • Thank you, Brian. To close, I want to reiterate that the progress we are making across the business is beginning to translate into broader recognition of the value of what we have built. Over the past several weeks, we have had the opportunity to engage with a growing number of important stakeholders, including global health organizations, government agencies and other decision-makers.

    謝謝你,Brian。在結尾,我想再次強調,我們在整個業務上取得的進展,正開始轉化為市場對我們所建立價值的更廣泛認可。在過去幾週,我們有機會與越來越多重要利害關係人交流,包括全球衛生組織、政府機構及其他決策者。

  • We believe those conversations are a clear indication of increasing interest in both our platform and the opportunities ahead of us. What is especially encouraging is that interest in TB testing is not limited to international markets. We are also seeing signs that the Co-Dx PCR platform and TB test may have meaningful relevance and broader point-of-care applications here in the United States.

    我們相信,這些對話清楚顯示市場對我們的平台以及未來機會的興趣正在提升。特別令人振奮的是,對結核病(TB)檢測的興趣並不限於國際市場。我們也看到跡象顯示,Co-Dx PCR平台與TB檢測在美國本土可能具有重要相關性,並可擴展至更廣泛的即時照護(point-of-care)應用。

  • We believe that position is the result of years of focused development, deliberate investment and a willingness to act on opportunities that align with our long-term vision. We did not arrive at this point by accident. We made intentional decisions to build a platform designed to address important unmet needs across multiple markets. And we believe those efforts are now beginning to open new opportunities for the company.

    我們相信,這樣的定位是多年來專注開發、審慎投資,以及願意把握與長期願景一致機會的成果。我們並非偶然走到今天這一步。我們做出有意識的決策,打造一個旨在滿足多個市場重要未被滿足需求的平台。我們也相信,這些努力如今正開始為公司開啟新的機會。

  • I also want to thank our shareholders for their continued support and patience, and our employees for their dedication and hard work. Their commitment continues to be one of the company's greatest strengths. We are encouraged by the momentum we are seeing and remain focused on execution. With that, let's open the line for questions. Operator?

    我也要感謝股東持續的支持與耐心,以及員工的投入與辛勤工作。他們的承諾一直是公司最重要的優勢之一。我們對目前看到的動能感到鼓舞,並將持續專注於執行。接下來,讓我們開放提問。接線員?

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Michael Okunewitch, Maxim Group.

    Michael Okunewitch,Maxim Group。

  • Michael Okunewitch - Equity Analyst

    Michael Okunewitch - Equity Analyst

  • Hey guys, thank you so much for taking my questions today. It looks like there's a lot of exciting stuff going on, great progress. I guess to start off, my question lies around scalability and your scale-up plans, since these are pretty big markets and you're approaching them fast. What's your current capacity for producing the test kits? And then what steps are you taking to enhance those capabilities?

    各位好,非常感謝今天讓我提問。看起來有很多令人振奮的事情正在進行,進展很大。我想先從可擴展性與你們的擴產計畫談起,因為這些市場規模很大,而你們也正快速切入。你們目前生產檢測試劑盒的產能是多少?接著,你們正在採取哪些步驟來提升這些能力?

  • Dwight Egan - Chairman of the Board, Chief Executive Officer

    Dwight Egan - Chairman of the Board, Chief Executive Officer

  • Thanks for the question. We believe that we are very well positioned to scale for initial commercial demand. Our Utah facility has already produced hundreds of thousands of test cups for clinical studies and in-house R&D. And we've been manufacturing and have manufacturing plans already designed and ready to implement in both the US, Saudi Arabia and also in India.

    謝謝你的提問。我們相信,我們在滿足初期商業需求的擴產方面具備非常良好的條件。我們位於猶他州的設施已為臨床研究與內部研發生產了數十萬個測試杯。此外,我們已在美國、沙烏地阿拉伯以及印度完成製造,並且已有設計完成、可立即執行的製造計畫。

  • As you may recall, CoSara, our India joint venture, inaugurated its oligo synthesis manufacturing facility in India at the end of 2024, and that will support Co-Primers' oligonucleotides manufacturing and commercialization in India. And over time, we think that the facility in India will also drive efficiency in our manufacturing process.

    如你所記得,CoSara(我們在印度的合資企業)於2024年底在印度為其寡核苷酸(oligo)合成製造設施舉行啟用儀式,這將支持Co-Primers在印度的寡核苷酸製造與商業化。隨著時間推進,我們也認為印度的該設施將提升我們製造流程的效率。

  • I'd point out that in the initial launch phase, the CoSara facility will be completing the final assembly of TB, HPV and upper respiratory test kits and instruments that are principally manufactured in Utah. The plan is over time to replicate portions of the Utah manufacturing process locally in India.

    我想指出,在初期上市階段,CoSara設施將完成TB、HPV及上呼吸道檢測試劑盒與儀器的最終組裝,而這些產品主要是在猶他州製造。長期計畫是逐步在印度當地複製猶他州製造流程的部分環節。

  • As you know, India represents one of the largest TB markets globally with high testing demand, strong alignment with WHO guidance. And our approach is simply to deliver the quality of PCR to significantly lower cost, and with greater accessibility, which we believe positions us competitively versus incumbent centralized solutions.

    如你所知,印度是全球最大的TB市場之一,檢測需求高,且與世界衛生組織(WHO)指引高度一致。我們的方法很簡單:以顯著更低的成本、並以更高的可近性,提供PCR的品質;我們相信,這使我們相較於既有的集中式解決方案具備競爭定位。

  • One other very interesting element of our preparation for scaling is that the Utah facility has been preparing an automated test cup manufacturing line that we expect will improve efficiency by approximately 4x in terms of time and overhead. So this is a very exciting development, and it not only increases our throughput capabilities by 4x, but it also gets rid of a lot of the potential human error factors that would happen along a line that would typically involve maybe 14 different human beings, which will now require the assistance of 1 or 2 on an automated line.

    我們為擴產所做準備中,另一個非常有趣的要素是:猶他州設施一直在準備一條自動化測試杯製造產線,我們預期在時間與間接費用方面可將效率提升約4倍。因此,這是一項非常令人振奮的發展;它不僅將我們的產出能力提升4倍,也消除了許多可能的人為錯誤因素——原本一條產線通常可能需要約14位不同人員參與,而在自動化產線上,將只需要1到2位人員協助。

  • So we're very excited about the prospects of the automated test cup. And it's not ready to go right now, but I've seen it demonstrated. And we expect that by the time we get to a certain point of deployment in Asia and in Saudi Arabia, that we'll be able to deploy the automated line.

    因此,我們對自動化測試杯的前景感到非常振奮。目前它還沒準備好立即上線,但我已看過示範。我們預期,等到我們在亞洲與沙烏地阿拉伯的部署進展到某個階段時,就能部署這條自動化產線。

  • Michael Okunewitch - Equity Analyst

    Michael Okunewitch - Equity Analyst

  • And then I do want to follow up on that because it seems like a large portion of your global strategy here is setting up specifically local manufacturing and local sales infrastructure. So can you talk a little bit about the advantages that you're seeking to leverage by going after these local regional manufacturing facilities?

    接著我確實想追問一下,因為看起來你們全球策略中很大一部分,是特別建立在地製造與在地銷售的基礎設施。所以你能否談談,透過布局這些在地、區域性的製造設施,你們希望運用哪些優勢?

  • Dwight Egan - Chairman of the Board, Chief Executive Officer

    Dwight Egan - Chairman of the Board, Chief Executive Officer

  • Well, we originally picked India as a joint venture partner basically nine years ago when we identified India as what was going to be, if not the biggest, certainly one of the biggest health care markets in the world. And that was a very good decision. And now we have a mature business entity that's been operating for nine years.

    我們最初在大約九年前選擇印度作為合資夥伴,基本上是因為我們判斷印度將會是——即使不是最大,也肯定是全球最大的醫療保健市場之一。而那是一個非常好的決定。如今我們已經有一個成熟的營運實體,運作了九年。

  • And we're ready now to transfer technology so they can locally manufacture the product and distribute it throughout the country. We've already serviced hundreds of laboratories in India. And so it's well prepped. There's a lot of expectation, we believe, for the initiation of our new wonderful platform, which emphasizes accessibility in terms of being able to get down to the end of the row.

    現在我們已準備好進行技術移轉,讓他們能在地製造產品並在全國範圍內進行分銷。我們已經服務過印度數百家實驗室。因此準備相當充分。我們相信,市場對於我們全新且出色的平台啟動有很高期待;該平台強調可近性,也就是能夠深入到最末端的據點。

  • There are 650,000 villages roughly in India that have no access or very little access to these types of diagnostics. And so we're going to be taking it to them and filling a huge gap. And it's not only accessibility. It's affordability. Our tests are competitively priced, of course.

    印度大約有65萬個村莊,對這類診斷幾乎沒有或只有非常有限的可近性。因此我們將把產品帶到他們那裡,填補巨大的缺口。而且不只是可近性。還有可負擔性。當然,我們的檢測定價具競爭力。

  • But our platform, the box that is used to actually perform the test, is a fraction of the cost of the competitive elements which are -- competitors, which are mainly targeted towards centralized hospitals and district hospitals in places like India. So we fill a huge gap. We're very excited to take it on.

    但我們的平台——也就是實際用來執行檢測的那台盒式設備——其成本僅為競品要素的一小部分;而競爭對手主要鎖定的是像印度這樣地區的集中式醫院與區域醫院。因此我們填補了一個巨大的缺口。我們非常期待推動這件事。

  • Michael Okunewitch - Equity Analyst

    Michael Okunewitch - Equity Analyst

  • All right. And then one more for me before I hop back into the queue. I wanted to see if you could expand a little bit on the actual go-to-market strategy in India. I imagine the clinical trial is largely going to be done in some of those larger medical centers rather than the smaller distributed microscopy centers that are the primary initial market here.

    好的。在我回到排隊之前,還有最後一個問題。我想請你再多談一點你們在印度實際的上市(go-to-market)策略。我猜臨床試驗大多會在一些較大型的醫療中心進行,而不是在那些較小、分散式的顯微鏡中心——那才是這裡初期的主要市場。

  • So I'd like to see if you could talk a little bit about how you plan to bridge that gap, build those relationships with the smaller centers, and if you have some of those relationships already established based on your existing work in India.

    所以我想請你談談,你們計畫如何彌補這個落差、如何與較小的中心建立關係,以及基於你們在印度既有的工作,是否已經建立了一些這類關係。

  • Dwight Egan - Chairman of the Board, Chief Executive Officer

    Dwight Egan - Chairman of the Board, Chief Executive Officer

  • Well, let me address the clinical trial first, which will begin shortly. We actually get assigned institutions that will perform the clinical trial. That is the locations, hospitals, district hospitals that will participate in the generation of the data and the testing that goes on there. Then once that finishes and we do the analytical studies, it's submitted to the CDSCO.

    好,我先談臨床試驗,臨床試驗將在不久後開始。實際上,會由主管機關指派執行臨床試驗的機構。也就是參與資料產出與現場檢測的地點——醫院、區域醫院等。接著一旦完成,我們進行分析研究後,就會提交給CDSCO。

  • I would point out that we've already been through this process a lot in India. We've got 15 tests that have been cleared through the CDSCO and that are molecular diagnostic tests. So we're very comfortable with the way that that's done and have an excellent track record in executing on it.

    我想指出的是,我們在印度已經多次走過這個流程。我們已有15項檢測通過CDSCO核准,且都是分子診斷檢測。因此我們對這套作業方式非常熟悉,並且在執行上有非常優異的紀錄。

  • So with respect to the kind of places where this is going to go, to fill the aforementioned gap that I referenced of 650,000 villages, and the primary health care facilities or PHCs where we intend these to land, this is an area where if you go into them, and I've been in these in my trips to India and looked at the actual types of facilities that we intend to be going into, and these are places where you go into them, there's a bunch of materials that are being used for smear microscopy, which is a 125-year-old technology.

    至於這將會落地到哪些類型的場所——為了填補我先前提到的65萬個村莊的缺口,以及我們打算讓產品進入的基層醫療機構或PHC——這一塊我很熟悉;我在前往印度的行程中曾走訪過這些地方,實地看過我們打算進入的設施類型。你走進去會看到一堆用於塗片顯微鏡檢查的材料,而那是一種已有125年歷史的技術。

  • It's only accurate 20% to 80% of the time, call it, a 50-50 gamble if you take one of those tests. It takes a lot of time. It takes time to get results. And this is what has to be replaced. The key opinion leaders around the world have designated going from smear microscopy to the kind of testing that we're doing, that is molecular diagnostics, as being the key driver in helping India overcome the epidemic of tuberculosis, which results in nearly 1,000 deaths every day. That's not 1,000 people who get TB, it's 1,000 people who die from it.

    它的準確率大概只有20%到80%,可以說做一次那種檢測就像五五波的賭注。它很耗時。取得結果也需要時間。而這正是必須被取代的部分。全球的關鍵意見領袖已指出,從塗片顯微鏡檢查轉向我們正在做的這類檢測——也就是分子診斷——是協助印度克服結核病流行的關鍵驅動因素;結核病每天造成近1,000人死亡。這不是每天有1,000人感染結核病,而是每天有1,000人死於結核病。

  • And so we're very excited about our ability to go there. We've spent a ton of time and have a fully-staffed group over there that has already been selling throughout the country. And I think we're very ready to go as soon as we get the clearance.

    因此我們對於能夠進入那裡感到非常振奮。我們投入了大量時間,並在當地建立了一支人員齊備的團隊,且已經在全國各地進行銷售。我認為一旦取得核准,我們就已經非常準備好立即推進。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • That concludes the Q&A session and our webcast. Thank you for your participation. You may now disconnect, and have a wonderful rest of your day.

    問答環節與我們的網路直播到此結束。感謝各位的參與。您現在可以斷線,祝您今天接下來一切順利。